Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ
Tytuł pozycji:

Role of Gastrointestinal Hormones as a Predictive Factor for Long-Term Diabetes Remission: Randomized Trial Comparing Metabolic Gastric Bypass, Sleeve Gastrectomy, and Greater Curvature Plication.

Tytuł :
Role of Gastrointestinal Hormones as a Predictive Factor for Long-Term Diabetes Remission: Randomized Trial Comparing Metabolic Gastric Bypass, Sleeve Gastrectomy, and Greater Curvature Plication.
Autorzy :
Casajoana A; Department of General and Gastrointestinal Surgery, Bariatric Surgery Unit, Bellvitge University Hospital-IDIBELL, Feixa Llarga s/n, L'Hospitalet de Llobregat, 08907, Barcelona, Spain.
Guerrero-Pérez F; Department of Endocrinology and Nutrition, Bellvitge University Hospital-IDIBELL, Feixa Llarga s/n, L'Hospitalet de Llobregat, 08907, Barcelona, Spain.
García Ruiz de Gordejuela A; Department of General Surgery, Endocrine, Bariatric and Metabolic Surgery Unit, Vall d'Hebron University Hospital, Ps Vall d'Hebron, 119-129, 08035, Barcelona, Spain.
Admella V; Department of General and Gastrointestinal Surgery, Bariatric Surgery Unit, Bellvitge University Hospital-IDIBELL, Feixa Llarga s/n, L'Hospitalet de Llobregat, 08907, Barcelona, Spain.
Sorribas M; Department of General and Gastrointestinal Surgery, Bariatric Surgery Unit, Bellvitge University Hospital-IDIBELL, Feixa Llarga s/n, L'Hospitalet de Llobregat, 08907, Barcelona, Spain.
Vidal-Alabró A; Bellvitge Biomedical Research Institute-IDIBELL, Feixa Llarga s/n, L'Hospitalet de Llobregat, 08907, Barcelona, Spain.
Virgili N; Department of Endocrinology and Nutrition, Bellvitge University Hospital-IDIBELL, Feixa Llarga s/n, L'Hospitalet de Llobregat, 08907, Barcelona, Spain.
Urdiales RL; Department of Endocrinology and Nutrition, Bellvitge University Hospital-IDIBELL, Feixa Llarga s/n, L'Hospitalet de Llobregat, 08907, Barcelona, Spain.
Montserrat M; Department of Endocrinology and Nutrition, Bellvitge University Hospital-IDIBELL, Feixa Llarga s/n, L'Hospitalet de Llobregat, 08907, Barcelona, Spain.
Pérez-Maraver M; Department of Endocrinology and Nutrition, Bellvitge University Hospital-IDIBELL, Feixa Llarga s/n, L'Hospitalet de Llobregat, 08907, Barcelona, Spain.
Monasterio C; Department of Pneumology, Sleep Unit, Bellvitge University Hospital-IDIBELL, Feixa Llarga s/n, L'Hospitalet de Llobregat, 08907, Barcelona, Spain.
Salord N; Department of Pneumology, Sleep Unit, Bellvitge University Hospital-IDIBELL, Feixa Llarga s/n, L'Hospitalet de Llobregat, 08907, Barcelona, Spain.
Pellitero S; Department of Endocrinology and Nutrition and Health Sciences Research Institute, University Hospital Germans Trias i Pujol, Badalona, Spain.
Fernández-Veledo S; Diabetes and Metabolic Associated Diseases Research Group, Hospital Universitari Joan XXIII-Institut d'Investigació Sanitària Pere Virgili, Tarragona, Spain.; CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain.
Vendrell J; Diabetes and Metabolic Associated Diseases Research Group, Hospital Universitari Joan XXIII-Institut d'Investigació Sanitària Pere Virgili, Tarragona, Spain.; CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain.; School of Medicine, Universitat Rovira i Virgili, Tarragona, Spain.
Gebelli JP; Department of General and Gastrointestinal Surgery, Bariatric Surgery Unit, Bellvitge University Hospital-IDIBELL, Feixa Llarga s/n, L'Hospitalet de Llobregat, 08907, Barcelona, Spain.
Vilarrasa N; Department of Endocrinology and Nutrition, Bellvitge University Hospital-IDIBELL, Feixa Llarga s/n, L'Hospitalet de Llobregat, 08907, Barcelona, Spain. .; CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain. .
Pokaż więcej
Źródło :
Obesity surgery [Obes Surg] 2021 Apr; Vol. 31 (4), pp. 1733-1744. Date of Electronic Publication: 2021 Jan 05.
Typ publikacji :
Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Język :
English
Imprint Name(s) :
Publication: 2006- : New York : Springer Science + Business Media
Original Publication: Oxford, OX, UK : Rapid Communications of Oxford, [1991-
MeSH Terms :
Diabetes Mellitus, Type 2*/surgery
Gastric Bypass*
Gastrointestinal Hormones*
Obesity, Morbid*/surgery
Gastrectomy ; Humans ; Treatment Outcome
References :
Scheen AJ, Van Gaal LF. Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes. Lancet Diabetes Endocrinol. 2014;2(11):911–22. (PMID: 24731666)
Heymsfield SB, Wadden TA. Mechanisms, pathophysiology, and Management of Obesity. N Engl J Med. 2017;376(15):254–66. (PMID: 28099824)
American Diabetes Association. Obesity management for the treatment of type 2 diabetes: standards of medical care in diabetes-2019. Diabetes Care. 2019;42(Suppl 1):S81–9.
Sjöström L, Peltonen M, Jacobson P, et al. Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. JAMA. 2014;311(22):2297–304. (PMID: 24915261)
Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric surgery versus intensive medical therapy for diabetes--3-year outcomes. N Engl J Med. 2014;370(21):2002–13. (PMID: 246790605451259)
Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial. Lancet. 2015;386(9997):964–73. (PMID: 26369473)
Ikramuddin S, Korner J, Lee W-J, et al. Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: the Diabetes Surgery Study randomized clinical trial. JAMA. 2013;309(21):2240–9. (PMID: 237367333954742)
Hofsø D, Fatima F, Borgeraas H, et al. Gastric bypass versus sleeve gastrectomy in patients with type 2 diabetes (Oseberg): a single-centre, triple-blind, randomised controlled trial. Lancet Diabetes Endocrinol. 2019;7(12):912–24. (PMID: 31678062)
Panunzi S, Carlsson L, De Gaetano A, et al. Determinants of diabetes remission and glycemic control after bariatric surgery. Diabetes Care. 2016;39(1):166–74. (PMID: 26628418)
McTigue KM, Wellman R, Nauman E, et al. Comparing the 5-year diabetes outcomes of sleeve gastrectomy and gastric bypass: the National Patient-Centered Clinical Research Network (PCORNet) Bariatric Study. JAMA Surg. 2020;155(5):e200087. (PMID: 32129809)
Gloy VL, Briel M, Mingrone G, et al. Bariatric surgery versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomised controlled trials. BMJ. 2013;347:f5934. (PMID: 241495193806364)
Salminen P, Helmio M, Ovaska J, et al. Effect of laparoscopic sleeve gastrectomy vs laparoscopic roux-en-y gastric bypass onweight loss at 5 years among patients with morbid obesity the SLEEVEPASS randomized clinical trial. JAMA. 2018;319(3):241–54. (PMID: 293406765833550)
Peterli R, Wölnerhanssen BK, Vetter D, et al. Laparoscopic sleeve Gastrectomy versus Roux-Y-gastric bypass for morbid obesity—3-year outcomes of the prospective randomized Swiss Multicenter Bypass Or Sleeve Study (SM-BOSS). Ann Surg. 2017;265(3):466–73. (PMID: 28170356)
Laferrère B, Pattou F. A gut check explains improved glucose metabolism after surgery. Cell Metab. 2019;30(5):852–4. (PMID: 31693881)
Rubino F, Forgione A, Cummings DE, et al. The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann Surg. 2006;244(5):741–9. (PMID: 170607671856597)
Batterham RL, Cummings DE. Mechanisms of diabetes improvement following bariatric/metabolic surgery. Diabetes Care. 2016;39(6):893–901. (PMID: 272225475864134)
Kamvissi V, Salerno A, Bornstein SR, et al. Incretins or anti-incretins? A new model for the “entero-pancreatic axis”. Horm Metab Res. 2015;47(1):84–7. (PMID: 25388925)
Hutch CR, Sandoval D. The role of GLP-1 in the metabolic success of bariatric surgery. Endocrinology. 2017;158(12):4139–51. (PMID: 290404295711387)
Gagner M. Hypoabsorptive surgery is the best revisional strategy for metabolic and diabetes outcomes. Surg Obes Relat Dis. 2020;16(10):1454–5. (PMID: 32773146)
Nora M, Guimarães M, Almeida R, et al. Metabolic laparoscopic gastric bypass for obese patients with type 2 diabetes. Obes Surg. 2011;21(11):1643–9. (PMID: 21512818)
Risstad H, Svanevik M, Kristinsson JA, et al. Standard vs distal roux-en-Y gastric bypass in patients with body mass index 50 to 60 a double-blind, randomized clinical trial. JAMA Surg. 2016;151(12):1146–55. (PMID: 27626242)
Clinical Issues Committee. ASMBS policy statement on gastric plication. Surg Obes Relat Dis. 2011;7(3):262.
Casajoana A, Pujol J, Garcia A, et al. Predictive value of gut peptides in T2D remission: randomized controlled trial comparing metabolic gastric bypass, sleeve gastrectomy and greater curvature plication. Obes Surg. 2017;27(9):2235–45. (PMID: 28451931)
Søvik TT, Taha O, Aasheim ET, et al. Randomized clinical trial of laparoscopic gastric bypass versus laparoscopic duodenal switch for superobesity. Br J Surg. 2010;97(2):160–6. (PMID: 20035530)
Wang MC, Guo XH, Zhang YW, et al. Laparoscopic Roux-en-Y gastric bypass versus sleeve gastrectomy for obese patients with type 2 diabetes: a meta-analysis of randomized controlled trials. Am Surg. 2015;81(2):166–71. (PMID: 25642879)
Wolever TM, Jenkins DJ, Jenkins RG, et al. The glycemic index: methodology and clinical implications. Am J Clin Nutr. 1991;54(5):846–54. (PMID: 1951155)
Kashyap SR, Bhatt DL, Wolski K, et al. Metabolic effects of bariatric surgery in patients with moderate obesity and type 2 diabetes: analysis of a randomized control trial comparing surgery with intensive medical treatment. Diabetes Care. 2013;36(8):2175–82. (PMID: 234396323714483)
Peterli R, Borbély Y, Kern B, et al. Early results of the Swiss Multicentre Bypass or Sleeve Study (SM-BOSS). Ann Surg. 2013;258(5):690–5. (PMID: 239890543888472)
Panunzi S, De Gaetano A, Carnicelli A, et al. Predictors of remission of diabetes mellitus in severely obese individuals undergoing bariatric surgery: do BMI or procedure choice matter? A meta-analysis. Ann Surg. 2015;261(3):459–67. (PMID: 25361217)
Barrichello S, Minata MK, García Ruiz de Gordejuela A, et al. Laparoscopic greater curvature plication and laparoscopic sleeve gastrectomy treatments for obesity: systematic review and meta-analysis of short- and mid-term results. Obes Surg. 2018;28(10):3199–212. (PMID: 29951784)
Sharples AJ, Mahawar K. Systematic review and meta-analysis of randomised controlled trials comparing long-term outcomes of Roux-en-Y gastric bypass and sleeve gastrectomy. Obes Surg. 2020;30(2):664–72. (PMID: 31724116)
Schauer PR, Mingrone G, Ikramuddin S, et al. Clinical outcomes of metabolic surgery: efficacy of glycemic control, weight loss, and remission of diabetes. Diabetes Care. 2016;39(6):902–11. (PMID: 272225485864131)
Yip S, Plank LD, Murphy R. Gastric bypass and sleeve gastrectomy for type 2 diabetes: a systematic review and meta-analysis of outcomes. Obes Surg. 2013;23(12):1994–2003. (PMID: 23955521)
Lee W-J, Chong K, Ser K-H, et al. Gastric bypass vs sleeve gastrectomy for type 2 diabetes mellitus: a randomized controlled trial. Arch Surg. 2011;146(2):143–8. (PMID: 21339423)
Cho J-M, Kim HJ, Lo Menzo E, et al. Effect of sleeve gastrectomy on type 2 diabetes as an alternative treatment modality to Roux-en-Y gastric bypass: systemic review and meta-analysis. Surg Obes Relat Dis. 2015;11(6):1273–80. (PMID: 26071847)
Rubino F, Marescaux J. Effect of duodenal-jejunal exclusion in a non-obese animal model of type 2 diabetes: a new perspective for an old disease. Ann Surg. 2004;239(1):1–11. (PMID: 146850931356185)
le Roux CW, Welbourn R, Werling M, et al. Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Ann Surg. 2007;246(5):780–5. (PMID: 17968169)
Fetner R, McGinty J, Russell C, et al. Incretins, diabetes, and bariatric surgery: a review. Surg Obes Relat Dis. 1(6):589–97.
Jirapinyo P, Jin DX, Thompson CC, et al. A meta-analysis of GLP-1 after Roux-en-Y gastric bypass: impact of surgical technique and measurement strategy. Obes Surg. 2018;28(3):615–26. (PMID: 28871519)
Jiménez A, Casamitjana R, Flores L, et al. GLP-1 and the long-term outcome of type 2 diabetes mellitus after Roux-en-Y gastric bypass surgery in morbidly obese subjects. Ann Surg. 2013;257(5):894–9. (PMID: 23579541)
Bradnova O, Kyrou I, Hainer V, et al. Laparoscopic greater curvature plication in morbidly obese women with type 2 diabetes: effects on glucose homeostasis, postprandial triglyceridemia and selected gut hormones. Obes Surg. 2014;24(5):718–26. (PMID: 24307436)
Nannipieri M, Baldi S, Mari A, et al. Roux-en-Y gastric bypass and sleeve gastrectomy: mechanisms of diabetes remission and role of gut hormones. J Clin Endocrinol Metab. 2013;98(11):4391–9. (PMID: 24057293)
Nagendra Gupta R, Chamany T, Makam R. Does length of common limb influence remission of diabetes? Short-term results. J Minim Access Surg. 2016;12(1):54–7.
Kaska Ł, Kobiela J, Proczko M, et al. Does the length of the biliary limb influence medium-term laboratory remission of type 2 diabetes mellitus after Roux-en-Y gastric bypass in morbidly obese patients? Wideochirurgia I Inne Tech Maloinwazyjne. 2014;9(1):31–9.
Guedes TP, Martins S, Costa M, et al. Detailed characterization of incretin cell distribution along the human small intestine. Surg Obes Relat Dis. 2015;11(6):1323–31. (PMID: 26048514)
Stefanidis D, Kuwada TS, Gersin KS. The importance of the length of the limbs for gastric bypass patients--an evidence-based review. Obes Surg. 2011;21(1):119–24. (PMID: 20680504)
Li J-F, Lai D-D, Ni B, et al. Comparison of laparoscopic Roux-en-Y gastric bypass with laparoscopic sleeve gastrectomy for morbid obesity or type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. Can J Surg. 2013;56(6):E158–64. (PMID: 242841563859791)
Kadera BE, Lum K, Grant J, et al. Remission of type 2 diabetes after Roux-en-Y gastric bypass is associated with greater weight loss. Surg Obes Relat Dis. 2015;5(3):305–9.
Contributed Indexing :
Keywords: Bariatric surgery*; Diabetes remission*; Greater curvature plication*; Metabolic gastric bypass*; Obesity*; Sleeve*; Type 2 diabetes mellitus*
Substance Nomenclature :
0 (Gastrointestinal Hormones)
Entry Date(s) :
Date Created: 20210105 Date Completed: 20210419 Latest Revision: 20210419
Update Code :
20210420
DOI :
10.1007/s11695-020-05192-x
PMID :
33398627
Czasopismo naukowe
Purpose: Long-term studies comparing the mechanisms of different bariatric techniques for T2DM remission are scarce. We aimed to compare type 2 diabetes (T2DM) remission after a gastric bypass with a 200-cm biliopancreatic limb (mRYGB), sleeve gastrectomy (SG), and greater curvature plication (GCP), and to assess if the initial secretion of gastrointestinal hormones may predict metabolic outcomes at 5 years.
Material and Methods: Forty-five patients with mean BMI of 39.4(1.9)kg/m 2 and T2DM with HbA 1c of 7.7(1.9)% were randomized to mRYGB, SG, or GCP. Anthropometric and biochemical parameters, fasting concentrations of PYY, ghrelin, glucagon, and AUC of GLP-1 after SMT were determined prior to and at months 1 and 12 after surgery. At 5-year follow-up, anthropometrical and biochemical parameters were determined.
Results: Total weight loss percentage (TWL%) at year 1 and GLP-1 AUC at months 1 and 12 were higher in the mRYGB than in the SG and GCP. TWL% remained greater at 5 years in mRYGB group - 27.32 (7.8) vs. SG - 18.00 (10.6) and GCP - 14.83 (7.8), p = 0.001. At 5 years, complete T2DM remission was observed in 46.7% after mRYGB vs. 20.0% after SG and 6.6% after GCP, p < 0.001. In the multivariate analysis, shorter T2DM duration (OR 0.186), p = 0.008, and the GLP-1 AUC at 1 month (OR 7.229), p = 0.023, were prognostic factors for complete T2DM remission at 5-year follow-up.
Conclusions: Long-term T2DM remission is mostly achieved with hypoabsortive techniques such as mRYGB. Increased secretion of GLP-1 after surgery and shorter disease duration were the main predictors of T2DM remission at 5 years.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies